President Donald Trump announced Monday that he would "soon" issue an order sanctioning Turkish officials, hiking tariffs on Turkish steel up to 50% and "immediately" halting...Politicsread more
Bloomberg could be in for a showdown with Elizabeth Warren, whether he runs or not.2020 Electionsread more
As the season kicks into gear this week, S&P 500 firms are expected to report a 4.6% earnings decline over the same period a year agoEarningsread more
"I think that may have scared the Chinese that they were going to get into a serious trade war with access to our capital markets being cut off, among other things," Michael...China Politicsread more
David Rolfe, a longtime Berkshire Hathaway shareholder and CIO at Wedgewood Partners, is fed up with Warren Buffett.Marketsread more
Bank of America says investors should still look to stocks for value rather than bonds.Investingread more
Wall Street analysts estimate GM has lost more than $1 billion due to the United Auto Workers' strike, which began Sept. 16.Autosread more
The indexes traded in a tight range as investors looked ahead to the start of the earnings season while grappling with new worries over trade.Marketsread more
Check out the companies making headlines in midday trading:Market Insiderread more
"The Champagne should probably be kept on ice, at least until the two presidents put pen to paper," said state-owned media China Daily.Traderead more
Shares of SmileDirectClub sank to a new all-time low during Monday's trading session after a California bill regulating the dental industry was extended through 2024.Marketsread more
The U.S. Food and Drug Administration on Tuesday said it approved Johnson & Johnson's nasal spray antidepressant that is chemically similar to often-abused ketamine, marking the first advance in treating depression in more than 30 years.
The treatment comes with a boxed warning — FDA's harshest — flagging the risk for sedation and difficulty with attention, judgment and thinking, abuse and misuse, and suicidal thoughts after administration of the drug.
Spravato nasal spray will be used along with a newly prescribed oral antidepressant, under supervision of health care professionals, the agency said.
Citing the risk of serious adverse outcomes and the potential for abuse and misuse, the FDA said the drug will be available through a restricted distribution system.
Spravato is a chemical mirror image of anesthetic ketamine, which is abused as a recreational party drug that goes by the street name Special K.
The decision comes after an FDA advisory panel recommended approval of the drug, Spravato, which is designed to treat depression in patients who have not benefited from two or more antidepressants.
"There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," said Tiffany Farchione of the FDA's Center for Drug Evaluation and Research.
Spravato has been touted as an asset with blockbuster potential and is expected to improve investor sentiment toward the growth prospects of J&J's pharma unit Janssen, as its top-selling rheumatoid arthritis drug Remicade faces increased competition from cheaper biosimilars.
The drug is also being tested in patients with depression who are at a high risk of committing suicide.